Paradigm Biopharmaceuticals Limited

Paradigm Biopharmaceuticals Limited

PBIGF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$4.1M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Paradigm Biopharmaceuticals LimitedParadigm Biopharmaceuticals Limited-1.6--2165%-2.2
$0.01

Current Fair Value

10.9% upside

Undervalued by 10.9% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$4.10 Million
Enterprise Value$-3,753,443.00
Earnings per Share$-0.16
Beta-0.02
Outstanding Shares344,426,096

Return

Return on Equity-2165.29%ROE
Return on Assets-245.96%
Return on Invested Capital-2179.31%

Valuation & Multiples

P/E Ratio-1.61P/E Ratio
PEG-1.02PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue-3.01
Enterprise Value to EBIT0
Enterprise Value to Net Income0
Total Debt to Enterprise-18.86
Debt to Equity2.16Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 27, 2026
EPS
-$0.07
Reported
Revenue
$38,033
Reported

Next Earnings Call

Expected Date
February 24, 2027
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Paradigm Biopharmaceuticals Limited

8 employees
CEO: Paul John Rennie

Melbourne, Australia-based Paradigm Biopharmaceuticals Limited operates as a drug repurposing company, focusing on the discovery and development of therapeutic products for human application. The company's core offering is an injectable ...